发布求助
文献互助 智能选刊 最新文献

Recenti progressi in medicina最新文献

筛选
英文 中文
Sicurezza degli integratori alimentari: dagli influencer alle segnalazioni del sistema italiano di fitosorveglianza. 食品补充剂的安全性：从影响因素到意大利植物监测系统发出的警告
Recenti progressi in medicina Pub Date : 2024-11-01 DOI: 10.1701/4365.43605
Ilaria Ippoliti, Roberto Da Cas, Giuseppe Marano, Arianna Annunziata, Emanuela Salvi, Paola Ruggeri, Francesca Menniti-Ippolito
{"title":"Sicurezza degli integratori alimentari: dagli influencer alle segnalazioni del sistema italiano di fitosorveglianza.","authors":"Ilaria Ippoliti, Roberto Da Cas, Giuseppe Marano, Arianna Annunziata, Emanuela Salvi, Paola Ruggeri, Francesca Menniti-Ippolito","doi":"10.1701/4365.43605","DOIUrl":"10.1701/4365.43605","url":null,"abstract":"<p><strong>Objectives: </strong>To assess the safety profile of dietary supplements with a focus on those purchased online or reported via the internet.</p><p><strong>Results: </strong>Among the 2,367 reports of Adverse Reactions (ARs) to dietary supplements collected within the Italian Phitovigilance System, 49.4% were from citizens and 33.7% from companies. From these we selected 129 reports (6%) in which an online purchase or an adverse reaction retrieved from the web was indicated (e.g. Amazon®). The most frequent ARs referred to the gastrointestinal tract (31.4%) and the central nervous system (17.6%). Nineteen percent were used for sleep disorders and 14% for disturbances of the prostate.</p><p><strong>Conclusions: </strong>The Italian Phytovigilance System is the only tool that provides information on the possible risks associated with the use of food supplements purchased online but the quality of the information collected needs to be improved.</p>","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"115 11","pages":"566-567"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142644629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Abortion in Italy (Law n.194/1978): what role for non-objecting doctors?] [意大利的堕胎（第194/1978号法律）：无异议医生的作用是什么？］
Recenti progressi in medicina Pub Date : 2024-11-01 DOI: 10.1701/4365.43583
Giuseppe R Gristina
{"title":"[Abortion in Italy (Law n.194/1978): what role for non-objecting doctors?]","authors":"Giuseppe R Gristina","doi":"10.1701/4365.43583","DOIUrl":"https://doi.org/10.1701/4365.43583","url":null,"abstract":"<p><p>Recently, talking about abortion, the Pope has spoken harshly regarding the role played by non-objecting doctors. The article discusses: 1) the ethical and health aspects that the denial of the right to terminate pregnancy entails; 2) the positive results obtained by non-objecting doctors 50 years after the implementation of Law no. 194/1978, in terms of safeguarding women's health and guaranteeing the implementation of a state law.</p>","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"115 11","pages":"505-506"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142643920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Sacituzumab govitecan in the second line treatment in a patient with triple-negative breast cancer with extensive locoregional recurrence.] [萨妥珠单抗-戈维替康用于广泛局部复发的三阴性乳腺癌患者的二线治疗]。
Recenti progressi in medicina Pub Date : 2024-11-01 DOI: 10.1701/4365.43611
Maria Vittoria Bonomo, Valeria Flaminio, Ilaria Portarena
{"title":"[Sacituzumab govitecan in the second line treatment in a patient with triple-negative breast cancer with extensive locoregional recurrence.]","authors":"Maria Vittoria Bonomo, Valeria Flaminio, Ilaria Portarena","doi":"10.1701/4365.43611","DOIUrl":"https://doi.org/10.1701/4365.43611","url":null,"abstract":"<p><p>Triple-negative breast cancer (TNBC) is a heterogeneous disease with an aggressive clinical course and worse outcomes than other breast cancer subtypes. Metastatic triple-negative breast cancer (mTNBC) is characterized by an aggressive clinical course and unfavorable outcomes, despite the pharmacological treatments used. The present clinical case describes a 35-year-old woman affected by TNBC characterized by rapid and subsequent local, cutaneous and lymph node progression of the disease. It was initially necessary to perform surgical treatment without the patient having completed neoadjuvant chemotherapy. 4 months after the end of adjuvant chemotherapy the patient underwent a second surgery. Then, she started the first line and, after 4 cycles, the second line with sacituzumab govitecan (SG) obtaining at the first instrumental re-evaluation a partial skin and lymph node response with a clear reduction in painful symptoms previously reported at the level of the right chest wall and axillary cavity. She continued treatment for a total of 9 cycles. The case confirms the clinical benefit and effectiveness of treatment with SG, in particular it underlines the good control of the disease characterized by a rapid and progressive course with exclusively locoregional extension and good control of symptoms with an improvement in quality of life.</p>","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"115 11","pages":"86e-89e"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142644427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Somatropin therapy in Italy during 2019-2022: prevalence and incidence rates estimated by data from the national register and regional health sources.] [2019-2022年期间意大利的索马里托品疗法：根据国家登记和地区卫生来源的数据估算的流行率和发病率]。
Recenti progressi in medicina Pub Date : 2024-11-01 DOI: 10.1701/4365.43585
Arianna Valerio, Daniela Rotondi, Roberto Da Cas, Flavia Pricci, Giuseppe Traversa
{"title":"[Somatropin therapy in Italy during 2019-2022: prevalence and incidence rates estimated by data from the national register and regional health sources.]","authors":"Arianna Valerio, Daniela Rotondi, Roberto Da Cas, Flavia Pricci, Giuseppe Traversa","doi":"10.1701/4365.43585","DOIUrl":"10.1701/4365.43585","url":null,"abstract":"<p><strong>Introduction: </strong>The availability of epidemiological data relating to the therapy with somatropin (recombinant Growth Hormone, rGH) is scarce and mostly limited to specific clinical conditions. In Italy, the National Register of rGH users (Registro nazionale degli assuntori dell'ormone della crescita - Rnaoc) has been established since 2004 as recommended by the Italian medicine agency (Aifa). However, prevalence (P) and incidence (I) estimates in the Italian population are lacking.</p><p><strong>Methods: </strong>Data from the Rnaoc and a questionnaire submitted to all the Italian regions have been used to calculate P and I rates of rGH treatment exposure in the Italian paediatric (0-17 years) and adult (≥18 years) population during 2019-2022; P and I rates of growth hormone deficiency (GHD) in paediatric patients have been estimated as well. Results from the two data sources have been compared.</p><p><strong>Results: </strong>In 2019-2022, the estimated P rate in the paediatric population was 13,4/10.000, in adults 0,7/10.000 inhabitants; the I rate was 2,3/10.000 and 0,06/10.000 inhabitants, correspondingly. The estimated P rate of paediatric GHD was 8,9/10.000, the I rate was 1,5/10.000 inhabitants, respectively.</p><p><strong>Conclusion: </strong>Study results showed a better reliability of data collected via questionnaire because more consistent with Italian regional resident populations.</p>","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"115 11","pages":"511-516"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142644434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mappatura di organizzazione e attività di ricerca sanitaria e biomedica delle Aziende sanitarie piemontesi. 绘制皮埃蒙特卫生机构的卫生和生物医学研究组织与活动图。
Recenti progressi in medicina Pub Date : 2024-11-01 DOI: 10.1701/4365.43592
Marta Betti, Serena Penpa, Alessia Melito, Franco Ripa, Adriano Leli, Antonio Maconi
{"title":"Mappatura di organizzazione e attività di ricerca sanitaria e biomedica delle Aziende sanitarie piemontesi.","authors":"Marta Betti, Serena Penpa, Alessia Melito, Franco Ripa, Adriano Leli, Antonio Maconi","doi":"10.1701/4365.43592","DOIUrl":"https://doi.org/10.1701/4365.43592","url":null,"abstract":"<p><p>In the Piedmont Region, the first mapping of the organization and research activity of the 18 Health Authorities was conducted in 2022 through the Research and Innovation Department (DAIRI), repeated in 2023. The data showed an increase in scientific production and research funding and a decrease in clinical research, although the most represented infrastructure is for the activation of clinical trials. The importance of creating a regional research system is highlighted.</p>","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"115 11","pages":"538-540"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142644621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sacituzumab govitecan nel trattamento delle pazienti pluritrattate affette da tumore della mammella triplo negativo metastatico. 萨妥珠单抗戈维替康用于治疗多次治疗的转移性三阴性乳腺癌患者。
Recenti progressi in medicina Pub Date : 2024-11-01 DOI: 10.1701/4365.43614
Marta Perachino, Matteo Lambertini
{"title":"Sacituzumab govitecan nel trattamento delle pazienti pluritrattate affette da tumore della mammella triplo negativo metastatico.","authors":"Marta Perachino, Matteo Lambertini","doi":"10.1701/4365.43614","DOIUrl":"https://doi.org/10.1701/4365.43614","url":null,"abstract":"","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"115 11","pages":"99e-101e"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142644626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Depression and effectiveness of psychedelics: high-dose psilocybin has shown benefits in improving symptoms.] [抑郁症和迷幻药的功效：大剂量迷幻药对改善症状有好处]。
Recenti progressi in medicina Pub Date : 2024-11-01 DOI: 10.1701/4365.43590
Viviana Forte, Allen F Shaughnessy, Peter K Kurotschka
{"title":"[Depression and effectiveness of psychedelics: high-dose psilocybin has shown benefits in improving symptoms.]","authors":"Viviana Forte, Allen F Shaughnessy, Peter K Kurotschka","doi":"10.1701/4365.43590","DOIUrl":"https://doi.org/10.1701/4365.43590","url":null,"abstract":"","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"115 11","pages":"525-526"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142644080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effetti sulla mortalità per causa delle emissioni dei principali impianti industriali nel “Bacino del fiume Sacco”: uno studio di coorte amministrativa. Bacino del fiume Sacco "地区主要工业厂房排放物对全因死亡率的影响：一项行政队列研究。
Recenti progressi in medicina Pub Date : 2024-11-01 DOI: 10.1701/4365.43594
Emanuela Carloni, Chiara Badaloni, Matteo Renzi, Alessandro Trentalange, Letizia Leccese, Daniela Porta, Paola Michelozzi
{"title":"Effetti sulla mortalità per causa delle emissioni dei principali impianti industriali nel “Bacino del fiume Sacco”: uno studio di coorte amministrativa.","authors":"Emanuela Carloni, Chiara Badaloni, Matteo Renzi, Alessandro Trentalange, Letizia Leccese, Daniela Porta, Paola Michelozzi","doi":"10.1701/4365.43594","DOIUrl":"10.1701/4365.43594","url":null,"abstract":"<p><p>The River Sacco Basin (Rsb) is a site of National interest, characterized by several environmental pressures such as industrial facilities. This study investigates the association between long-term exposure to industrial-PM10 and -NOx and cause-specific mortality (non-accidental, cardiovascular, respiratory, and cancer) in the Rsb in the 2006-2018 period. We enrolled 301,681 residents near 14 major industrial plants (grouped into 5 30-km2 spatial domains). Residential exposure to annual PM10 and NOx was considered as categorical exposure (high (>80th percentile), medium (50th-80th), and low (<50th)). We applied adjusted domain specific Cox regression models (covariates: age, sex, and deprivation index) and performed a relative meta-analysis. We obtain a pooled 34% increase in respiratory mortality for high PM10 levels. Elevated risks were also observed for non-accidental and cancer mortality, highlighting the need for continuous monitoring and preventive interventions.</p>","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"115 11","pages":"543-544"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142644497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Long-term efficacy and safety with sacituzumab govitecan in a patient with triple-negative breast cancer, multi-treated and high body mass index.] [萨希妥珠单抗戈维替康对一名三阴性乳腺癌患者的长期疗效和安全性，该患者接受过多种治疗且体重指数较高。］
Recenti progressi in medicina Pub Date : 2024-11-01 DOI: 10.1701/4365.43617
Maria Morritti
{"title":"[Long-term efficacy and safety with sacituzumab govitecan in a patient with triple-negative breast cancer, multi-treated and high body mass index.]","authors":"Maria Morritti","doi":"10.1701/4365.43617","DOIUrl":"10.1701/4365.43617","url":null,"abstract":"<p><p>The metastatic triple negative breast cancer (mTNBC) represents a particularly aggressive form of breast cancer that frequently affects young women under the age of 50. Obesity at the time of breast cancer diagnosis is associated with a worse prognosis. Compared to the recent past, increasing life expectancy and quality of life for patients with mTNBC is now a possible challenge, thanks to a new drug, sacituzumab govitecan (SG), an anti-Trop-2 antibody drug conjugate approved as monotherapy for the treatment of these patients. The presented clinical case documents the efficacy and safety of long-term treatment with SG in an obese young woman with mTNBC who has already undergone multiple treatments. The patient is still responding after 20 months of treatment with good quality of life and social interactions.</p>","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"115 11","pages":"110e-115e"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142644369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Use of sacituzumab govitecan in frail patients with skin disease.] [在患有皮肤病的体弱患者中使用萨希珠单抗戈维替康]。
Recenti progressi in medicina Pub Date : 2024-11-01 DOI: 10.1701/4365.43615
Eugenia Arrivas Bajardi
{"title":"[Use of sacituzumab govitecan in frail patients with skin disease.]","authors":"Eugenia Arrivas Bajardi","doi":"10.1701/4365.43615","DOIUrl":"https://doi.org/10.1701/4365.43615","url":null,"abstract":"<p><p>The clinical case described concerns a 53-year-old patient with triple-negative disease, metastatic to the skin, fragile, not due to comorbidities, but due to toxicities from previous antiblastic treatments. The major toxicities reported, even previously, were inherent to bone marrow function, with prolonged neutropenia, despite the use of granulocyte growth factor (GCSF). The patient has no family history of breast cancer and does not have a mutation in the BRCA1/2 genes. In pathological history, only arterial hypertension under medical therapy with nebivolol.</p>","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"115 11","pages":"102e-104e"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142644566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信